Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides

Urology

Volumn 54, Issue 6 SUPPL. 1, 1999, Pages 36-46

  Gleave, Martin E ^a,b   Miayake, Hideaki ^a,b   Goldie, Jim ^c   Nelson, Colleen ^a,b   Tolcher, Anthony ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOCETAXEL; MESSENGER RNA; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; GENE OVEREXPRESSION; GENE TARGETING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR CELL;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; DISEASE PROGRESSION; DNA PRIMERS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENE TARGETING; GENES, BCL-2; MALE; MICE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TAXOIDS;

EID: 0032785072     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00453-7     Document Type: Article

References (33)

1. Denis L., Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 72:1993;3888-3895.
2. Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer current standards and future prospects . J Urol. 160:1998;1220-1229.
3. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50:1990;2275-2282.
4. McDonnell T.J., Troncoso P., Brisby S.M., Logothetis C.L., Chung L.W.K., Hsieh J.T., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
5. Colombel M., Symmans F., Gil S., O'Toole K.M., Choplin D., Benson M., et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 143:1993;390-400.
6. Berchem G.J., Bosseler M., Sugars L.Y., Voeller H.J., Zeitlin S., Gelmann E.P. Androgen-induced resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55:1995;735-738.
7. Raffo A.J., Periman H., Chen M.W., Streitman J.S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:1995;4438-4445.
8. Tsujimoto Y., Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 83:1986;5214-5218.
9. Sato T., Hanada M., Bodnig S., Ine S., Iwana N., Boise L.H., et al. Interactions among members of the bcl-2 protein family analysed with a yeast two-hybrid systems. Proc Natl Acad Sci USA. 91:1994;9238-9242.
10. McConkey D.J., Greene G., Pettaway C.A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 56:1996;5594-5599.
11. Crooke S.T. Progress in antisense oligonucleotides. Annu Rev Pharmacol Toxicol. 36:1996;107-129.
12. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2:1996;668-675.
13. Zieger A., Luedke G.H., Fabbro D., Altman K.-H., Stahel R.A., Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 89:1997;1027-1036.
14. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A, Muller M., et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4:1998;232-234.
15. Zangemeister-Wittke U., Schenker T., Luedke G.H., Stahel R.A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer. 78:1998;1035-1042.
16. Schultz M., Wei J., Picus J., Cochran J. A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC) (abstract number 1320). Proc Am Soc Clin Oncol. 18:1999;355a.
17. Friedland D, Cohen J, Miller R, et al.: A phase II trial of Taxotere in hormone refractory prostate cancer: correlation of antitumor activity to phosphorylation of bcl2 (abs). Proc Am Soc Clin Oncol 18:322A, 1999.
18. Halder S., Basu A., Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
19. Gleave M.E., Hsieh J.T., Wu H.-C., Chung L.W.K. Serum PSA levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors. Cancer Res. 52:1992;1598-1605.
20. Miyake H., Hanada N., Nakamura H., Kagawa S., Fujiwara T., Hara I., et al. Overexpression of bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene. 16:1998;933-943.
21. L is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 58:1998;3331-3338.
22. Gleave M.E., Hsieh J.T., Gao C., von Eschenbach AC, Chung L.W.K. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51:1991;3753-3761.
23. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371:1994;346-347.
24. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
25. Saijo Y., Perlaky L., Wang H., Busch H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res. 6:1994;243-249.
26. Ollikainen H., Lappalainen K., Jaaskelainen I., Syrjanen S., Pulkki K. Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell line. Leuk Lymphoma. 24:1996;165-174.
27. Campos L., Sabido O., Rouault J.P., Guyotat D. Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 84:1994;595-600.
28. Smith M.R., Abubakr Y., Mohammad R., Xie T., Hamdan M., Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther. 2:1995;207-212.
29. Harnois D.M., Que F.G., Celli A., LaRusso N.F., Gores G.J. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology. 26:1997;884-890.
30. Zhang X., Jackson J.K., Burt H.M. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 132:1996;195-206.
31. Ramaswamy M., Zhang X., Burt H.M., Wasan K.M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci. 86:1997;460-464.
32. Gleave ME, Tolcher A, Miyake H, Beraldi E, and Goldie J: Antisense bcl-2 oligos delay progression to androgen-independence after castration in the LNCaP prostate tumor model. Clin Cancer Res (in press).
33. Miyake H., Tolcher A., Gleave M.E. Antisense bcl-2 oligodeoxynucleotides enhance chemosensitivity to taxol in the androgen dependent Shionogi tumor model. J Urol. 161:1999;130A.